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Abstract
Background:  HIV envelope glycoprotein (Env)-mediated fusion is driven by the concerted
coalescence of the HIV gp41 N-helical and C-helical regions, which results in the formation of 6
helix bundles. Kinetics of HIV Env-mediated fusion is an important determinant of sensitivity to
entry inhibitors and antibodies. However, the parameters that govern the HIV Env fusion cascade
have yet to be fully elucidated. We address this issue by comparing the kinetics HIV-1IIIB Env with
those mediated by HIV-2 from two strains with different affinities for CD4 and CXCR4.
Results: HIV-1 and HIV-2 Env-mediated cell fusion occurred with half times of about 60 and 30
min, respectively. Binding experiments of soluble HIV gp120 proteins to CD4 and co-receptor did
not correlate with the differences in kinetics of fusion mediated by the three different HIV Envs.
However, escape from inhibition by reagents that block gp120-CD4 binding, CD4-induced CXCR4
binding and 6-helix bundle formation, respectively, indicated large difference between HIV-1 and
HIV-2 envelope glycoproteins in their CD4-induced rates of engagement with CXCR4.
Conclusion: The HIV-2 Env proteins studied here exhibited a significantly reduced window of
time between the engagement of gp120 with CD4 and exposure of the CXCR4 binding site on
gp120 as compared with HIV-1IIIB Env. The efficiency with which HIV-2 Env undergoes this CD4-
induced conformational change is the major cause of the relatively rapid rate of HIV-2 Env
mediated-fusion.
Background
The origins of Human Immunodeficiency Virus (HIV) can
be traced to zoonotic transmissions of Simian Immuno-
deficiency Virus (SIV) to humans from at least two differ-
ent kinds of non-human primates [1]: HIV-1, which came
from chimpanzees, and HIV-2, which came from sooty
mangabeys. While similar in many ways, there are impor-
tant differences between HIV-1 and HIV-2 that provide
insights into virus evolution, tropism and pathogenesis
[2]. Major differences include reduced pathogenicity of
HIV-2 relative to HIV-1, enhanced immune control of
HIV-2 infection and often some degree of CD4-independ-
ence. Despite considerable sequence and phenotypic dif-
ferences between HIV-1 and 2 envelopes, structurally they
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are quite similar. Both membrane-anchored proteins
eventually form the 6-helix bundles from the N-terminal
and C-terminal regions of the ectodomain [3], which is
common to many viral and cellular fusion proteins and
which seems to drive fusion [4]. HIV-1IIIB gp41 helical
regions can form more stable 6-helix bundles than HIV-
2SBL gp41 helical regions [3,5]; however HIV-2 fusion
occurs at a lower threshold temperature (25°C), does not
require Ca2+ in the medium, is insensitive to treatment of
target cells with cytochalasin B [6], and is not affected by
target membrane glycosphingolipid composition [7].
In order to elucidate mechanisms of HIV envelope glyco-
protein-mediated fusion we have kinetically resolved
steps in the pathway of HIV-1 membrane fusion [8]. To
gain a better understanding of the molecular mechanisms
underlying these steps, we compared kinetic parameters
of HIV-1IIIB with two strains of HIV-2. We found a signifi-
cant difference in fusion kinetics, which appears to be
related to the CD4-induced rate of engagement of HIV
gp120 with its coreceptor. Since the CD4-induced binding
of gp120 proteins to CXCR4 is not very different between
the different strains, we surmise that in the intact Env
other regions (e.g. the cytoplasmic tail) may have a pro-
found influence on the conformational changes in the
surface-exposed portions of the envelope glycoproteins.
Results
Fusion kinetics
We examined the dye transfer that occurs as result of
fusion between HeLa cells infected with recombinant vac-
cinia viruses expressing Env proteins and labeled with a
red tracker dye and target SupT1 cells labeled with calcein
at different times of co-culture at 37°C. Figure 1 shows
that once cells expressing HIV-1IIIB Env were mixed with
SupT1 cells, fusion began after a lag phase at 37°C of
about 30 min, with 50% of maximum fusion (t1/2) occur-
ring at 63 ± 6 min. HIV-2SBL and HIV-2ROD Env-mediated
fusion, on the other hand, showed no appreciable lag
time and 50% of maximum fusion was reached in 23 ± 4
and 28 ± 2 minutes, respectively.
Binding of HIV-1 and HIV-2 gp120 to CD4 and CXCR4
In previous studies we have found that fusion rates can be
dependent on the affinity with which an Env binds to its
coreceptor [9,10]. Potentially, differences in CD4 affinity
could also impact fusion kinetics. We therefore performed
studies to assess the binding of soluble gp120s derived
from each of the virus strains to CXCR4 or CD4. Cells
expressing no receptor (pcDNA3 transfected), CD4 or
CXCR4 were incubated with equivalent amounts of puri-
fied HIV-1 or HIV-2 gp120s with or without the presence
of soluble CD4 (to allow CXCR4 binding), and were then
washed, lysed and assayed for binding through Western
blot analysis (Figure 2). HIV-2ROD gp120 bound CD4
poorly as compared with HIV-2SBL gp120, but HIV-2ROD
gp120 exhibited stronger binding to CXCR4 as compared
to HIV-2SBL gp120. HIV-1IIIB gp120 was more similar to
HIV-2SBL gp120 in its CD4 and CXCR4 binding profile
than HIV-2ROD gp120 (Figure 2). Specificity of binding
was demonstrated by sCD4 inhibition of CD4 binding
and a lack of CXCR4 binding in the absence of sCD4 (data
not shown).
These binding data were further corroborated by inhibi-
tion studies of HIV-1 and HIV-2-mediated fusion. Dose-
response curves were generated for inhibition of gp120-
CD4 binding by Leu3A, and for gp120-CXCR4 binding by
AMD3100. Table 1 shows the IC50 values derived from
these curves. Higher amounts of inhibitor are required to
displace ligands with high affinity for their receptor, pro-
vided that the ligands bind in a similar fashion. The high
IC50 for inhibition of HIV-2ROD by AMD3100 (Table 1) is
entirely consistent with its binding potency shown in fig-
ure 2. HIV-1IIIB and HIV-2SBL, on the other hand, had low
IC50's for inhibition by AMD3100 (Table 1) consistent
with low affinity for CXCR4 as suggested by the data in fig-
ure 2. The gp120-CD4 binding data shown in figure 2 are
also consistent with inhibition of fusion by Leu3A. HIV-
2ROD showed little binding to CD4, and its IC50 for inhi-
bition by Leu3A was the lowest compared to HIV-1IIIB and
Kinetics of HIV-1 and HIV-2 Env-mediated fusion Figure 1
Kinetics of HIV-1 and HIV-2 Env-mediated fusion. 
HIV-1IIIB (squares), HIV-2SBL (triangles), and HIV-2ROD (cir-
cles) Env proteins were expressed in HeLa cells using vac-
cinia recombinants as described in Materials and Methods. 
Target SupT1 cells, labeled with calcein, were added to the 
plated HeLa cells, labeled with CMTMR, at various times dur-
ing a two hour period at 37°C. The cells were then examined 
by fluorescence microscopy for dye transfer indicating cell-
cell fusion. Lines represent fits to the sigmoidal equation f = 
a/(1-exp [-b(t - t1/2)]) using Sigmaplot (SPSS, Chicago). Values 
of time for half maximal fusion (t1/2) are 63 ± 6, 28 ± 2 and 23 
± 4 minutes for HIV-1IIIB, HIV-2SBL and HIV-2ROD, respec-
tively.
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HIV-2SBL. The latter two showed binding to CD4 in the
Western blot assay and had higher IC50 values. The bind-
ing of HIV-1 and HIV-2 gp120 to CD4 and CXCR4 per se
does therefore not appear to account for the differences in
fusion kinetics.
Escape from inhibition by Leu3A and C34
In previous studies we had dissected the kinetics of HIV-1
Env-mediated fusion by adding inhibitors that act at the
various steps of the fusion reaction [11] at different times
following co-culture of Env-expressing cells with target
cells. In those studies we observed a large time differential
between losses of sensitivity to Leu3A as compared to
AMD3100. However, loss of sensitivity to C34 occurred
nearly concomitantly with loss of sensitivity to AMD3100
indicating that the HIV-1 gp41 6-helix bundle formation
occurs rapidly after the engagement of gp120 by CXCR4
in the HIV-1 env-mediated fusion process. In order to ana-
lyze the rate-limiting step in HIV-2SBL  Env-mediated
fusion we performed similar loss of sensitivity studies.
Previously we had shown that SIV C34 is a good inhibitor
of HIV-1 as well as HIV-2 fusion [3]. We used concentra-
tions of C34 at which HIV-2SBL Env-mediated fusion was
completely inhibited. Figure 3 shows that the kinetics of
loss of sensitivity to Leu3A, AMD3100 and C34 were
indistinguishable with t1/2's of about 27 min, indicating
that the HIV-2 envelope glycoprotein assumes its CXCR4-
grabbing conformation very rapidly after engagement
with CD4.
Discussion
The current model of HIV viral entry involves the binding
of the trimeric viral Env glycoprotein gp120/gp41 to cell
surface receptor CD4, which triggers conformational
changes in the envelope proteins. Gp120 is then re-posi-
tioned allowing gp41 to undergo conformational changes
that result in the formation of the gp41 "pre-hairpin" [12-
14]. Upon engagement with chemokine co-receptors
CXCR4 or CCR5 [15,16], the C-terminal heptad repeat
region and the leucine/isoleucine zipper region form the
thermostable 6-helix bundle, which drives membrane
merger and eventual fusion [17]. In the case of HIV-1IIIB it
appears that the pre-hairpin conformation is quite a long
lasting state [11,18]. Previously, we had attributed the rel-
atively slow kinetics of HIV-1 Env-mediated fusion to the
stochastic nature of HIV Env triggering giving rise to a rel-
atively low probability of 6-helix bundle formation and
fusion [8]. We had invoked the "harpoon" model [15]
according to which the HIV-1 gp120 is searching to
engage its co-receptor following initial conformational
changes induced by CD4 binding. We had shown that
HIV-1 gp41 6-helix bundle formation occurs rapidly after
the engagement of gp120 by CXCR4 in the HIV-1 Env-
mediated fusion process [11]. We reasoned that higher
gp120-coreceptor affinities may result in more rapid
Table 1: Inhibition of HIV-1 and HIV-2 Env-mediated fusion. 
AMD3100 or Leu3A were added to cocultures of HIV-expressing 
cells and target cells at the time of co-culture and fusion was 
measured as described in Methods. IC50 values were derived 
from dose-response by fitting the data to a hyperbolic decay 
function.
IC50 (µg/ml) for fusion at 37°C
AMD3100 Leu3A
HIV-1IIIB 0.53 ± 0.07 0.3 ± 0.1
HIV-2ROD >10 0.03 ± 0.02
HIV-2SBL 0.14 ± 0.02 0.09 ± 0.01
Binding of soluble gp120 to cellular CD4 orCXCR4 Figure 2
Binding of soluble gp120 to cellular CD4 orCXCR4. 
Receptor binding efficiencies of gp120s were determined 
using a cell surface-binding assay in which bound protein was 
detected by Western blot analysis as described in Materials 
and Methods. Binding to CXCR4 was performed in the pres-
ence of sCD4 to expose the coreceptor binding site. HIV-
1IIIB and HIV-2SBL gp120 exhibited relatively high CD4 binding 
efficiencies but weak CXCR4 binding. HIV-2ROD gp120 exhib-
ited relatively weak binding to CD4 and relatively high bind-
ing to CXCR4. Numbers indicate mean band intensity 
following subtraction of background pcDNA3 lane intensity.
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gp120-coreceptor binding leading to enhanced rates of 6-
helix formation and fusion. This hypothesis has been
born out in studies showing that envelope:coreceptor
affinity correlates with fusion kinetics [9,10].
In this study we show that fusion mediated by the HIV-
1IIIB Env exhibits slower kinetics as compared to that of
two different HIV-2 Envs (Figure 1). Since we observed lit-
tle CD4-induced binding of gp120 from HIV-1IIIB and
HIV-2SBL to CXCR4 under steady-state condition (figure
2), and similar AMD3100 susceptibilities (Table 1) that
are in contrast to efficient CXCR4 binding and markedly
reduced AMD3100 susceptibility for HIV-2ROD, the differ-
ence in fusion rates mediated by these HIV-1 and HIV-2
Envs are not likely due to differences in gp120-coreceptor
affinity per se. However, the time of addition experiments
(figure 3) indicate that the major difference in kinetics
between HIV-1IIIB and HIV-2SBL lays in the efficiency of
conformational changes that occur after CD4 is bound
and that result in the formation of the coreceptor-binding
site. In the case of HIV-1, exposure of the coreceptor bind-
ing site has not yet occurred immediately after the stage
that Leu3A can block. It has been shown that binding of a
single CD4 molecule to an envelope trimer leads to con-
formational changes in all three gp120 molecules [19].
This process may take a relatively long time in the case of
HIV-1 Env. By contrast, the coreceptor binding site is rap-
idly exposed following CD4 binding in the case of HIV-2
Env consistent with the observation that HIV-2 strains (in
contrast to HIV-1) are often able to infect cells CD4-inde-
pendently. Since CD4-induced binding of soluble gp120
molecules to CXCR4 was not very different between the
HIV-1IIIB  and HIV-2SBL  strains, we surmise that in the
intact Env other regions may have a profound influence
on this conformational change.
In order to examine other regions that may affect the rate
of HIV Env-mediated fusion we performed a sequence
comparison between HIV-1HxB2 (which is similar to HIV-
1IIIB) and the two HIV-2 strains studied in this paper (fig-
ure 4). The regions considered important for fusion
(fusion peptide, N-helical region, membrane proximal
region and transmembrane anchor seem to be well con-
served between the strains. The C-helical regions appear to
be dissimilar which could account for the differences in 6-
helix bundle stabilities between HIV-1IIIB and HIV-2 [3,5].
However, the differences in gp41 refolding into 6-helix
bundles in the intact envs do not correlate with 6-helix
bundle stabilities of the peptides derived from those
regions.
Another region of HIV-1 gp41 that has profound effects
on fusion rates is the cytoplasmic tail [20]. HIV-1, HIV-2
and SIV CTs are remarkably long and contain domains
that likely interact with host cell components, such as cal-
modulin [21,22], α-catenin [21], p115-RhoGEF [23], Pre-
nylated Rab acceptor protein [24], or AP-1 clathrin
adaptor proteins [25]. Three alpha helical "lentivirus lytic
peptide" domains (LLP-1, LLP-2 and LLP-3) highly con-
served in HIV-1 have been implicated in interacting with
the cytoplasmic leaflet of plasma membrane, decreasing
bilayer stability, altering membrane ionic permeability,
and mediating cell killing [26-28]. Poorly defined regions
of gp41 have also been implicated in interacting with viral
matrix proteins during virion assembly [29,30]. This inter-
action also modulates Env function in that gp41 is more
stably associated with immature rather than mature viral
particles [30], and cleavage of the p55 Gag precursor pro-
tein by the viral protease is required to generate Envs with
maximal fusogenicity [31,32].
Truncations of gp41 proximal to the most N-terminal
alpha helix, LLP-2, produced a significant increase in the
rate of HIV-1 Env-mediated cell fusion [20,33]. These
effects were not seen with a truncation distal to this
domain and before LLP1 [20]. These results were observed
for X4-, R5-, and dual-tropic Envs on CXCR4- and CCR5-
expressing target cells. Sequence comparisons of gp41
derived from HIV-1, HIV-2 and SIV indicate high homol-
ogy between the three viral Envs in the LPP-1 region but
not in the LLP-2 region of the cytoplasmic tail (the
sequence comparisons can be obtained from Brian Foley
Time course for escape from HIV-2SBL Env-mediated fusion  inhibition Figure 3
Time course for escape from HIV-2SBLEnv-mediated 
fusion inhibition. Fusion was measured as described in the 
legend to figure 1. Leu3A (3 µg/ml, triangles), AMD3100 (40 
µM, circles) and SIV C34 (2 µM, squares) were added at dif-
ferent times following co-culture at 37°C and residual fusion 
was measured following their time of addition. The curves 
were fitted by the sigmoidal function given in the legend to 
figure 1; values of time for half maximal fusion (t1/2) are 26.9 
± 4.1, 24.8 ± 6.4 and 26.4 ± 2.3 minutes for Leu3A (green), 
AMD3100 (red) and C34 (blue), respectively.
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upon request). In the case of certain HIV-1 Env strains it
has been shown that CT truncations prior to LLP-2 pro-
foundly affect the exposure of CD4-induced epitopes on
gp120 [20,34], indicating that "inside-out" signalling
changes the conformation in the Env ectodomain.
Although we have performed this analysis by comparing
only one HIV-1 and two HIV-2 strains we believe that the
methodology developed here can be expanded to include
comparisons between various strains of HIV-1 and HIV-2.
Future studies that involve domain swapping between
HIV-1 and HIV-2 gp41 CT's will determine whether our
LLP-2 hypothesis turns out to be correct.
Conclusion
We find that the differences in fusion mediated by HIV-1
and HIV-2 Env are due to the rates by which the Envs
assume a conformation that expose the binding sites on
gp120 to the CXCR4 following engagement with CD4. In
spite of the fact that CD4-induced binding to CXCR4 of
isolated gp120 derived from HIV-1IIIB and HIV-2SBL were
similar, their rate of binding to the co-receptor was mark-
edly different in the context of the complete Envs. We
speculate that sequences in the cytoplasmic tail of the Env
may have a profound influence upon the rate by which
the extracytoplasmic portion of gp120 assumes its
CXCR4-engageable conformation.
Methods
Cells
QT6, 293T and HeLa cell lines were cultured in DMEM
supplemented with 10% fetal calf serum, 60 mg/ml of
penicillin and 100 mg/ml streptomycin. Sup-T1 cells
Sequence comparison of HIV-1 and HIV-2 Envs Figure 4
Sequence comparison of HIV-1 and HIV-2 Envs. The HIV-1 subtype B infectious molecular clone HXB2 Env gp41 
sequence (Database accession number K03455) is aligned to the HIV-2 ROD (M15390) and ISY (J04498) Env gp41 sequences. 
Amino Acid sites conserved in all 3 sequences are shaded black, and those conserved in 2 of the 3 are shaded grey. Numbering 
is based on the HXB2 amino acid sequence. The sequences corresponding approximately to the different regions of HIV-1 
gp41 have been highlighted as follows: Membrane Anchor (180–203), red; Lentivirus Lytic Peptide-3 (268–286), green; Lentivi-
rus Lytic Peptide-2 (287–313), cyan; Lentivirus Lytic Peptide-1 (326–354), turquoise. Note the lack of homology in LLP-2 and 3 
sequences, whereas LLP-1 (337–354) appears to be very homologous between the three strains.Retrovirology 2006, 3:90 http://www.retrovirology.com/content/3/1/90
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(Non-Hodgkin's T-cell lymphoma cell line) were cultured
in RPMI supplemented with 10% serum, 60 mg/ml of
penicillin and 100 mg/ml streptomycin.
Inhibitors
The fusion inhibitor SIV C34 [3] was dissolved in PBS at a
stock concentration of 500 uM. The CXCR4 antagonist
AMD3100 [35], a kind gift from Anormed, Inc. (Langley,
Canada), was dissolved in PBS at a stock concentration of
1 µg/ul. Leu3A, an antibody against the gp120 binding
site of CD4 and a highly effective fusion inhibitor [36]
(BD Biosciences, San Jose, CA), was dissolved in 0.1%
Azide at 25 ug/ml. All inhibitors were stored at 4°C.
Plasmids
The 3' half proviral clone of HIV-2SBL (KF-3; kindly pro-
vided by G. Franchini) was used as a template for PCR
amplification of the envelope gene using 5' CACCAT-
GAGTGGTAAAATTCAGCTGC 3' and 5' CTCCTTGCTGA-
TATCTCTGTCCCTCA 3' oligonucleotides. The PCR
product was cloned into the pcDNA3.1 D/V5-His-TOPO
expression vector (Invitrogen, Carlsbad, CA) to generate
an sbl/isy gp160 expression construct. A stop codon was
introduced at the gp120/gp41 cleavage junction of the
sbl/isy gp160 expression construct using the 'Quikchange'
site directed mutagenesis kit (Stratagene, La Jolla, CA) and
5' GGGAGACATAAGAGATGAAAGCTTGTGCTAG-
GGTTC 3' and 5' GAACCCTAGCACAAGCTTTCATCTCT-
TATGTCTCCC 3' oligonucleotides to generate a gp120
expression construct. These oligonucleotides also intro-
duce an HindIII restriction enzyme site (for screening pur-
poses) down stream of the stop codon. HIV-2ROD/A and
HIV-1IIIB gp120 expression vectors have been described
previously [37,38].
Vaccinia recombinants
HIV-1 and HIV-2 Env proteins were expressed in HeLa
cells using the following vaccinia recombinants;vPE16,
for the IIIB strain of HIV-1 [39], vvROD, for the ROD
strain of HIV-2 [40], and vSC50 for the SBL/ISY strain of
HIV-2 [41]. These recombinants were incubated with cells
overnight at a ratio of 10:1 infectious virions to cells. HeLa
cells were plated on 12 or 24 well plates overnight before
infection (Costar, Cambridge, MA). The recombinant
vTF1.1 vaccinia virus encoding T7 polymerase was used to
drive expression of plasmids with the T7 promoter.
Cell-Cell fusion assay
For dye transfer assays [11], HeLa cells infected with
recombinant vaccinia viruses expressing Env proteins and
labeled with CMTMR (494/517, red) and target SupT1
cells labeled with Calcein (541/565, green) in suspension
were co-cultured (Molecular Probes, Eugene, OR). Kinetic
experiments were conducted in which target SupT1 cells
in suspension in 37°C media were added to plated effec-
tor cells at various times during a two hour period. The
cells were then examined by fluorescence microscopy for
dye transfer between Env and receptor expressing cells
indicating cell-cell fusion. Phase and fluorescent images
were collected using an Olympus IX70 coupled to a CCD
camera (Princeton Instruments, Trenton, NJ) with a 10×
objective lens. An 82000 optical filter cube (Chroma
Technology Corp., Brattleboro, VT) was used for the exci-
tation of calcein and CMTMR. Three images per well were
collected and then analyzed using Metamorph software
(Universal Imaging, West Chester, PA) for dye transfer
from the donor to the acceptor cell. The scoring of fusion
events was conducted as previously described [18]. The
results were normalized by the control fusion and
expressed as a percentage. Curves for fusion inhibition
assays were fitted, using a hyperbolic decay function, and
the IC50 was extracted. Fusion kinetics curves were fit to a
sigmoidal function and the half time, at which 50%
fusion was achieved, was extracted.
Env:Receptor binding assay
gp120s were produced from 293T cells calcium phos-
phate transfected with gp120 expression constructs and
infected with vTF1.1 vaccinia virus. Cell culture superna-
tants were harvested 24 hours post transfection/infection
and gp120 concentrations determined by ELISA as previ-
ously described [42] with the exception that different anti-
bodies were utilized. Receptor binding efficiencies of
gp120s were determined using a cell surface-binding assay
in which bound protein is detected by Western blot anal-
ysis [38,43]. Briefly, 2 × 106 QT6 target cells were calcium
phosphate transfected with 6 ug pcDNA3.1 (control),
CD4 or CXCR4 expression plasmids in 25 cm2 culture
flasks and infected with vTF1.1 to boost expression. 24 hrs
post-transfection/infection, cells were incubated with
gp120 for 2 hours at room temperature with and without
5 ug/ml soluble CD4 (sCD4) to trigger coreceptor binding
site exposure. Cells were washed 3× with cold PBS to
remove unbound gp120 then lysed with NP40 lysis buffer
(0.5% NP40, 150 mM NaCl, 50 mM Tris pH 8) on ice for
10 minutes. Clarified lysates were assayed for gp120 con-
tent by SDS-PAGE and Western blotting and detected with
an HIV-1 Env specific rabbit serum and an HRP-conju-
gated anti-rabbit antibody (Amersham Life Science, Pis-
cataway, NJ) or a HIV-2 Env reactive MAb and an HRP-
conjugated anti-mouse antibody (Promega, Madison, WI)
followed by Supersignal chemiluminescent substrate
(Pierce, Rockford, IL). Band intensity was quantitated
using Kodak 1D software.
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